Artificial Hormone might Replace Sunscreen.

AST-OPC1 was administered to both individuals by the lead neurosurgeon for the clinical trial, Dr. Richard Fessler, Professor of Neurological Surgery at Hurry. Dr. Fessler stated, ‘I am extremely encouraged by the excellent safety data that we have seen in our two sufferers to date and I anticipate the dose escalation phase of the analysis.’ Dr. Edward Wirth, Chief Medical Officer of Asterias, said ‘We are happy with the confirmation of security in the first dosage cohort and so are excited to begin with recruitment of patients who’ll receive the higher dosage of 10 million AST-OPC1 cells, which we believe corresponds to the doses that demonstrated efficacy in pet studies.’ The open-label, single-arm trial is being conducted at three centers currently and will include up to twelve centers in the United States.Botulinum toxin A was connected with a greater decrease in average headache intensity than methylprednisolone in one trial among sufferers experiencing chronic tension-type head aches , the authors create. Our analyses claim that botulinum toxin A could be connected with improvement in the regularity of chronic migraine and chronic daily head aches, however, not with improvement in the rate of recurrence of episodic migraine, chronic tension-type head aches, or episodic tension-type head aches.

Other entries from category "endocrinology":

Random entries